HIV-chemotherapy and -prophylaxis: New drugs, leads and approaches

International Journal of Biochemistry and Cell Biology

Volumn 36, Issue 9, 2004, Pages 1800-1822

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Anti HIV drugs; Chemoprophylaxis; Chemotherapy; HIV

Indexed keywords

2' DEOXY 3' OXA 4' THIOCYTIDINE; 6 CHLORO 4 (2 CYCLOPROPYLVINYL) 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; ABACAVIR; ADEFOVIR DIPIVOXIL; AMDOXOVIR; ANTIBIOTIC AGENT; ATAZANAVIR; CAPRAVIRINE; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYCLOTRIAZADISULFONAMIDE DERIVATIVE; ELVUCITABINE; EMIVIRINE; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; GLYCOPEPTIDE ANTIBIOTIC DERIVATIVE; IMIDAZOLE DERIVATIVE; INTEGRASE INHIBITOR; LAMIVUDINE; LECTIN; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; N AMINOIMIDAZOLE DERIVATIVE; PROTEIN INHIBITOR; PYRANODIPYRIMIDINE V 165; PYRIDINE DERIVATIVE; PYRIDINE OXIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFONAMIDE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS ENVELOPE PROTEIN; ZALCITABINE; ZIDOVUDINE;

CELL FUSION; CELL SURFACE; CHEMOTHERAPY; CLINICAL TRIAL; CYST; CYTOLOGY; DRUG BIOAVAILABILITY; ERYTHEMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTEGRATION; MODULATION; PROPHYLAXIS; REVIEW; SKIN NODULE; TRANSCRIPTION INITIATION; VIRUS ENVELOPE;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; ANTIGENS, CD4; CHEMOPREVENTION; DOWN-REGULATION; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HUMANS; MOLECULAR SEQUENCE DATA; NUCLEOSIDES; NUCLEOTIDES; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 2942627670     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2004.02.015     Document Type: Review

References (125)

1. Andries, K., de Béthune, M.- P., Kukla, M. J., Azijn, H., Lewi, P. J., & Janssen, P. A. J., et al. (2000). R165335-TMC125, a novel non nucleoside reverse transcriptase inhibitor (NNRTI) with nanomolar activity against NNRTI resistant HIV strains. In Proceedings of the Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (no. 1840). Toronto, Canada, 17-20 September 2000.
2. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proceedings of National Academy of Sciences of United States of America. 96:1999;5698-5703
3. Baba M., Okamoto M., Takeuchi H. Inhibition of human immunodeficiency virus type 1 replication in acutely and chronically infected cells by EM2487, a novel substance produced by a Streptomyces species. Antimicrobial Agents and Chemotherapy. 43:1999;2350-2355
4. Balzarini, J., Hatse, S., Vermeire, K., Princen, K., De Clercq, E., & Egberink, et al. (2003). Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides to prevent infection and transmission of the human immunodeficiency virus, Submitted for publication.
5. Balzarini J., Naesens L., Verbeken E., Laga M., Van Damme L., Parniak M., et al. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. Acquired Immunodeficiency Syndrome. 12:1998;1129-1138
6. Balzarini J., Pannecouque C., De Clercq E., Pavlov A.Y., Printsevskaya S.S., Miroshnikova O.V., et al. Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics. Journal of Medical Chemistry. 46:2003;2755-2764
7. Balzarini J., Pauwels R., Herdewijn P., De Clercq E., Cooney D.A., Kang G.J., et al. Potent and selective anti-HTLV-III/LAV activity of 2′, 3′-dideoxycytidinene, the 2′, 3′-unsaturated derivative of 2′, 3′-dideoxycytidine. Biochemical and Biophysical Research Communication. 140:1986;735-742
8. Balzarini, J., Van Laethem, K., Hatse, S., Vermeire, K., De Clercq, E., & Peumans, et al. (2003). Unique resistance profile of human immunodeficiency virus against mannose-specific plant lectins, Submitted for publication.
9. Benhamou Y., Tubiana R., Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. New English Journal of Medicine. 348:2003;177-178
10. Borkow G., Barnard J., Nguyen T.M., Belmonte A., Wainberg M.A., Parniak M.A. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: Retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. Journal of Virology. 71:1997;3023-3030
11. Botos I., Wlodawer A. Cyanovirin-N: A sugar-binding antiviral protein with a new twist. Cellular and Molecular Life Science. 60:2003;277-287
12. Boyd M.R., Gustafson K.R., McMahon J.B., Shoemaker R.H., O'Keefe B.R., Mori T., et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development. Antimicrobial Agents and Chemotherapy. 41:1997;1521-1530
13. Bray B.L. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nature Review and Drug Discovery. 2:2003;587-593
14. Castonguay L.A., Weng Y., Adolfsen W., Di Salvo J., Kilburn R., Caldwell C.G., et al. Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1, 3, 4-trisubstituted pyrrolidines to human CCR5: A molecular modeling-guided mutagenesis study of the binding pocket. Biochemistry. 42:2003;1544-1550
15. Chao S.H., Fujinaga K., Marion J.E., Taube R., Sausville E.A., Senderowicz A.M., et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. Journal of Biological Chemistry. 275:2000;28345-28348
16. Chiu Y.L., Ho C.K., Saha N., Schwer B., Shuman S., Rana T.M. Tat stimulates cotranscriptional capping of HIV mRNA. Molecular Cell. 10:2002;585-597
17. Colonno R.J., Thiry A., Limoli K., Parkin N. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrobial Agents and Chemotherapy. 47:2003;1324-1333
18. Corbett J.W., Ko S.S., Rodgers J.D., Jeffrey S., Bacheler L.T., Klabe R.M., et al. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy. 43:1999;2893-2897
19. Corbett J.W., Ko S.S., Rodgers J.D., Gearhart L.A., Magnus N.A., Bacheler L.T., et al. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. Journal of Medical Chemistry. 43:2000;2019-2030
20. Daelemans D., Esté J.A., Witvrouw M., Pannecouque C., Jonckheere H., Aquaro S., et al. S-Adenosylhomocysteine hydrolase inhibitors interfere with the replication of human immunodeficiency virus type 1 through inhibition of the LTR transactivation. Molecular Pharmacology. 52:1997;1157-1163
21. Daelemans D., Schols D., Witvrouw M., Pannecouque C., Hatse S., van Dooren S., et al. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: Inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. Molecular Pharmacology. 57:2000;116-124
22. Daelemans D., Afonina E., Nilsson J., Werner G., Kjems J., De Clercq E., et al. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proceedings of National Academy of United States of America. 99:2002;14440-14445
23. Daelemans D., Vandamme A.M., De Clercq E. Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy. Antiviral Chemistry and Chemotherapy. 10:1999;1-14
24. Dayam R., Neamati N. Small-molecule HIV-1 integrase inhibitors: The 2001-2002 update. Current Pharmaceutical Design. 9:2003;1789-1902
25. de Béthune, M., Wigerinck, P., Jonckheere, H., Tahri, A., Maes, L., & Pauwels, R., et al. (2001). TMC 114, a highly potent protease inhibitor (PI) with an excellent profile against HIV variants highly resistant to current Pis. In Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, USA, 16-19 December 2001, Abstracts F-1677.
26. De Clercq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Research. 38:1998;153-179
27. De Clercq, E (2003). New anti-HIV agents in preclinical or clinical development. Frontiers in medicinal chemistry, in press
28. De Clercq E. The bicyclam AMD3100 story. Nature Review and Drug Discovery. 2:2003;581-587
29. De Clercq E. Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections. Expert Review Anti-infection Therapy. 1:2003;21-43
30. Dragic T., Trkola A., Thompson D.A., Cormier E.G., Kajumo F.A., Maxwell E., et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proceedings of National Academy of United States of America. 97:2000;5639-5644
31. Ena J., Pasquau F. Once-a-day highly active antiretroviral therapy: A systemic review. Clinical Infection and Disease. 36:2003;1186-1190
32. Erickson-Viitanen S., Wu J.-T., Shi G., Unger S., King R.W., Fish B., et al. Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIV. Antiviral Chemistry and Chemotherapy. 14(14):2003;39-47
33. Fikkert V., Van Maele B., Vercammen J., Hantson A., Van Remoortel B., Michiels M., et al. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. Journal of Virology. 77:2003;11459-11470
34. Furman P.A., Jeffrey J., Kiefer L.L., Feng J.Y., Anderson K.S., Borroto-Esoda K., et al. Mechanism of action of 1-β-D-2, 6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-β-D-dioxolane guanosine. Antimicrobial Agents and Chemotherapy. 45:2001;158-165
35. Gazzard, B., Pozniak, A., Arasteh, K., Staszewski, S., Rozenbaum, W., & Yeni, P., et al. (2002). TMC125, a next-generation NNRTI, demonstrates high potency after 7 days therapy in treatment-experienced HIV-1-infected individuals with phenotypic NNRTI resistance. In: Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections (no. 4, p. 54). Seattle, Washington, USA, 24-28 February 2002, Abstracts.
36. Geleziunas R., Gallagher K., Zhang H., Bacheler L., Garber S., Wu J.-T., et al. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor β-D-2′, 3′-dideoxy-2′, 3′-didehydro-5- fluorocytidine (Reverset™). Antiviral Chemistry and Chemotherapy. 14:2003;49-59
37. Goldgur Y., Craigie R., Cohen G.H., Fujiwara T., Yoshinaga T., Fujishita T., et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proceedings of National Academy of United States of America. 96:1999;13040-13043
38. Gong Y.F., Robinson B.S., Rose R.E., Deminie C., Spicer T.P., Stock D., et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrobial Agents and Chemotherapy. 44:2000;2319-2326
39. Grobler J.A., Stillmock K., Hu B., Witmer M., Felock P., Espeseth A.S., et al. Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes. Proceedings of National Academy of United States of America. 99:2002;6661-6666
40. Haas D.W., Zala C., Schrader S., Piliero P., Jaeger H., Nunes D., et al. Therapy with atazanavir plus saquinavir in patients failing highly active antretroviral therapy: A randomized comparative pilot trial. Acquired Immunodeficiency Syndrome. 17:2003;1339-1349
41. Hale J.J., Budhu R.J., Holson E.B., Finke P.E., Oates B., Mills S.G., et al. 1, 3, 4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2. Lead optimization affording selective % orally bioavailable compounds with potent anti-HIV activity. Bioorganic Medical Chemistry and Letters. 11:2001;2741-2745
42. Hale J.J., Budhu R.J., Mills S.G., MacCoss M., Gould S.L., DeMartino J.A., et al. 1, 3, 4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3. Polar functionality and its effect on anti-HIV-1 activity. Bioorganic Medical Chemistry and Letters. 12:2002;2997-3000
43. Hamy F., Felder E.R., Heizmann G., Lazdins J., Aboul-ela F., Varani G., et al. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proceedings of the National Academy of Sciences of United States of America. 94:1997;3548-3553
44. Hazen R., Lanier E.R. Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type. Journal of Acquired Immune Deficiency Syndrome. 32:2003;255-258
45. Hazuda D.J., Felock P., Witmer M., Wolfe A., Stillmock K., Grobler J.A., et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 287:2000;646-650
46. Heil, M., Decker, J., Chen, D.- T., Sfakianos, J., Shaw, G., & Hunter, E., et al. (2003). Analysis of patient-derived HIV-1 isolates suggests a novel mechanism for decreased sensitivity to inhibition by enfuvirtide and T-649. In Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections (no. 615). Boston, MA, USA, 10-14 February 2003, Abstracts.
47. Hendrix C.W., Flexner C., MacFarland R.T., Giandomenico C., Fuchs E.J., Redpath E., et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR4-chemokine receptor, in human volunteers. Antimicrobial Agents and Chemotherapy. 44:2000;1667-1673
48. Ichiyama K., Yokoyama-Kumakura S., Tanaka Y., Tanaka R., Hirose K., Bannai K., et al. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proceedings of National Academy of United States of America. 100:2003;4185-4190
49. Iizawa, Y., Kanzaki, N., Takashima, K., Miyake, H., Tagawa, Y., & Sugihara, Y., et al. (2003). Anti-HIV-1 activity of TAK-220, a small molecule CCR5 antagonist. In Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections (no. 11). Boston, MA, USA, 10-14 February 2003, Abstracts.
50. Jeffrey J.L., Feng J.Y., Qi C.C.R., Anderson K.S., Furman P.A. Dioxolane guanosine 5′-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Journal of Biological Chemistry. 278:2003;18971-18979
51. Jemsek, J. G., Arathoon, E., Arlotti, M., Perez, C., Sosa, N., & Giordano, M., et al. (2003). Atazanavir and efavirenz, each combined with fixed-dose zidovudine and lamivudine, have similar effects on body fat distribution in antiretroviral-naïve patients: 48-week results from the metabolic substudy of BMS AI424-034. In Proceedings of the 2nd IAS Conference on HIV and Pathogenesis. Paris, France, 14-17 July 2003, Abstracts.
52. Katlama, C., Arastéh, K., Clotet, B., Cooper, D., Henry, K., & Lalezari, J., et al. (2003). Enfuvirtide TORO studies: 48 week results confirm 24 week findings. In Proceedings of the 2nd IAS Conference on HIV and Pathogenesis. Paris, France, 14-17 July 2003, Abstracts.
53. Ketas T.J., Klasse P.J., Spenlehauer C., Nesin M., Frank I., Pope M., et al. Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. Acquired Immunodeficiency Syndrome Res. Hum. Retrovir. 19:2003;177-186
54. Kewn S., Wang L.H., Hoggard P.G., Rousseau F., Hart R., MacNeela J.P., et al. Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients. Antimicrobial Agents and Chemotherapy. 47:2003;255-261
55. Kilby J.M., Hopkins S., Venetta S.M., DiMassimo B., Cloud G.A., Lee J.Y., et al. Potent suppression of HIV-1 replication in humans by T-20% a peptide inhibitor of gp41-mediated virus entry. Natural Medicine. 4:1998;1302-1307
56. King P.J., Robinson W.E. Jr. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. Journal of Virology. 72:1998;8420-8424
57. King P.J., Lee D.J., Reinke R.A., Victoria J.G., Beale K., Robinson W.E. Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors. Virology. 306:2003;147-161
58. Lagoja I.M., Pannecouque C., Musumeci L., Froeyen M., Van Aerschot A., Balzarini J., et al. 1, 2, 4-Triazole derivatives inhibiting the human immunodeficiency virus type 1 (HIV-1) in vitro. Helves Chimica Acta. 85:2002;1883-1892
59. Lagoja I.M., Pannecouque C., Van Aerschot A., Witvrouw M., Debyser Z., Balzarini J., et al. N-aminoimidazole derivatives inhibiting retroviral replication via a yet unidentified mode of action. Journal of Medical Chemistry. 46:2003;1546-1553
60. Lalezari J.P., Henry K., O'Hearn M., Montaner J.S.G., Piliero P.J., Trottier B., et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. New English Journal of Medicine. 348:2003;2175-2185
61. Larder B.A., Hertogs K., Bloor S., van den Eynde C.H., DeCian W., Wang Y., et al. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. Acquired Immunodeficiency Syndrome. 14:2000;1943-1948
62. Lazzarin A., Clotet B., Cooper D., Reynes J., Arastéh K., Nelson M., et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. New English Journal of Medicine. 348:2003;2186-2195
63. Louie M., Hogan C., Hurley A., Simon V., Chung C., Padte N., et al. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naïve chronically HIV-1-infected individuals. Acquired Immunodeficiency Syndrome. 17:2003;1151-1156
64. Louie M., Hogan C., Di Mascio M., Hurley A., Simon V., Rooney J., et al. Determining the relative efficacy of highly active antiretroviral therapy. Journal of Infection and Disease. 187:2003;896-900
65. Lynch C.L., Gentry A.L., Hale J.J., Mills S.G., MacCoss M., Malkowitz L., et al. CCR5 antagonists: Bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidines. Bioorganic Medical Chemistry and Letters. 12:2002;677-679
66. Lynch C.L., Hale J.J., Budhu R.J., Gentry A.L., Mills S.G., Chapman K.T., et al. 1, 3, 4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4. Synthesis of N-1-acidic functionality affording analogues with enhanced antiviral activity against HIV. Bioorganic Medical Chemistry and Letters. 12:2002;3001-3004
67. Maeda K., Yoshimura K., Shibayama S., Habashita H., Tada H., Sagawa K., et al. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. Journal of Biological Chemistry. 276:2001;35194-35200
68. Maeda, K., Nakata, H., Miyakawa, T., Ogata, H., Koh, Y., & Takaoka, Y., et al. (2002). Novel HIV-specific spirodiketopiperazine CCR5 inhibitors potent against a wide spectrum of R5-HIV, HIV DART 2002. Frontiers in drug development for antiretroviral therapies (no. 014). Naples, FL, USA, 15-19 December 2002; Antiviral Research, 2002, Abstracts.
69. Marcelin, A. G., Tubiana, R., Benhamou, Y., Katlama, C., Calvez, V., & Thibault, V. (2003). Long-term tenofovir treatment of lamivudine-resistant chronic hepatitis B in HIV co-infected patients. In Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections (no. 824). Boston, MA, USA, 10-14 February 2003, Abstracts.
70. Margot N.A., Isaacson E., McGowan I., Cheng A., Miller M.D. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: Genotypic, phenotypic, and rebound analyses. Journal of Acquired Immune Deficiency Syndrome. 33:2003;15-21
71. McCallister, S., Sabo, J., Galitz, L., & Mayers, D. (2002). An open-label steady state investigation of the pharmacokinetics (PK) of tipranavir (TPV) and ritonavir (RTV) and their effects on cytochrome P-450 (3A4) activity in normal health volunteers (BI 1182.5). In Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections (no. 434-W). Seattle, Washington, USA, 24-28 February 2002, Abstracts.
72. Mewshaw J.P., Myrick F.T., Wakefield D.A.C.S., Hooper B.J., Harris J.L., McCreedy B., et al. Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails. Journal of Acquired Immune Deficiency Syndrome. 29:2002;11-20
73. Molina J.M., Ferchal F., Rancinan C., Raffi F., Rozenbaum W., Sereni D., et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. Journal of Infection and Disease. 182:2000;599-602
74. Montaner, J., DeMasi, R., Delehanty, J., Chung, J., Gafoor, Z., & Salgo, M. (2003). Analysis of virological response of enfuvirtide in TORO: Implications for patient management. In Proceedings of the 2nd IAS Conference on HIV and Pathogenesis. Paris, France, 14-17 July 2003, Abstracts.
75. Mori T., Boyd M.R. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells. Antimicrobial Agents and Chemotherapy. 45:2001;664-672
76. Murphy, R. L., Schürmann, D., Kravec, I., Eron, J., Havlir, D., & Beard, A., et al. (2002). Pharmacokinetics and safety of the nucleoside reverset in HIV-1 infected patients, HIV DART 2002. Frontiers in drug development for antiretroviral therapies (no. 074). Naples, FL, USA, 15-19 December 2002; Antiviral Research, 2002, Abstracts.
77. Nunez M., Pérez-Olmeda M., Diaz B., Rios P., Gonzalez-Lahoz J., Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. Acquired Immunodeficiency Syndrome. 16:2002;2352-2354
78. Okamoto H., Cujec T.P., Okamoto M., Peterlin B.M., Baba M., Okamoto T. Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37. Virology. 272:2000;402-408
79. ® in male volunteers, HIV DART 2002. Frontiers in drug development for antiretroviral therapies (no. 044). Naples, FL, USA, 15-19 December 2002; Antiviral Research, 2002, Abstracts.
80. Painter, G. R., St. Claire, R., Feng, J., & Borroto-Esoda, K. (2002). Anabolic profile of the dioxolane nucleoside analogue DXG in human PBMC; reversal of resistance by boosting 5′-triphosphate levels. In Proceedings of the Fifteenth International Conference on Antiviral Research (no. 7). Prague, Czech Republic, 17-21 March 2002; Antiviral Research 53, A37.
81. Palani A., Shapiro S., Clader J.W., Greenlee W.J., Vice S., McCombie S., et al. Oximino-piperidino-piperidine-based CCR5 antagonists. Part 2. Synthesis, SAR and biological evaluation of symmetrical heteroaryl carboxamides. Bioorganic Medical Chemistry and Letters. 13:2003;709-712
82. Pannecouque C., Pluymers W., Van Maele B., Tetz V., Cherepanov P., De Clercq E., et al. New class of HIV integrase inhibitors that block viral replication in cell culture. Current Biology. 12:2002;1169-1177
83. Pluymers W., Neamati N., Pannecouque C., Fikkert V., Marchand C., Burke T.R. Jr., et al. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Molecular Pharmacology. 58:2000;641-648
84. Pluymers W., Pais G., Van Maele B., Pannecouque C., Fikkert V., Burke T.R. Jr., et al. Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives. Antimicrobial Agents and Chemotherapy. 46:2002;3292-3297
85. Poppe S.M., Slade D.E., Chong K.T., Hinshaw R.R., Pagano P.J., Markowitz M., et al. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrobial Agents and Chemotherapy. 41:1997;1058-1063
86. Raffi, F., Saag, M., Cahn, P., Wolff, M., Pearce, D., & Molina, J., et al. (2003). A randomized, double-blind, multicenter comparison of emtricitabine QD to stavudine BID in treatment-naïve HIV-infected patients. In Proceedings of the 2nd IAS Conference on HIV and Pathogenesis. Paris, France, 14-17 July 2003, Abstracts.
87. Ren J., Nichols C., Bird L.E., Fujiwara T., Sugimoto H., Stuart D.I., et al. Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse trancriptase involves extensive main chain hydrogen bonding. Journal of Biological Chemistry. 275:2000;14316-14320
88. Reynes, J., Rouzier, R., Kanouni, T., Baillat, V., Baroudy, B., & Keung, A. (2002). SCH C: Safety and antiviral effects of a CCR5 receptor antagonist in HIV-1 infected subjects. In Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections (no. 1, p. 53). Seattle, Washington, USA, 24-28 February 2002, Abstracts.
89. Richman D.D. Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor. Antiviral Therapy. 6:2001;83-88
90. Rimsky L.T., Shugars D.C., Matthews T.J. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. Journal of Virology. 72:1998;986-993
91. Ristig M.B., Crippin J., Aberg J.A., Powderly W.G., Lisker-Melman M., Kessels L., et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-α and lamivudine therapy have failed. Journal of Infection and Disease. 186:2002;1844-1847
92. Rousseau F.S., Kahn J.O., Thompson M., Mildvan D., Shepp D., Sommadossi J.P., et al. Prototype trial design for rapid dose selection of antiretroviral drugs: An example using emtricitabine (Coviracil). Journal of Antimicrobial and Chemotherapy. 48:2001;507-513
93. Ruiz, N., Nusrat, R., Lauenroth-Mai, E., Berger, D., Walworth, C., & Bacheler, L. T., et al., The DPC 083-203 Study Team (2002). Study DPC 083-203, a phase II comparison of 100 and 200 mg once-daily DPC 083 and 2 NRTIs in patients failing a NNRTI-containing regimen. In Proceeding sof the 9th Conference on Retroviruses and Opportunistic Infections (no. 6, p. 55). Seattle, Washington, USA, 24-28 February 2002, Abstracts.
94. Ruiz, N., Nusrat, R., Lazzarin, A., Arasteh, K., Goebel, F.-D., & Audagnotto, S., et al. (2002). A phase II double-blind (DB) comparison of 3 once daily doses of the NNRTI DPC 083 vs. 600 mg efavirenz (EFV) in combination with 2 NRTIs in HIV antiretroviral (ARV) treatment-naïve patients. In Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections (no. 7, p. 55). Seattle, Washington, USA, 24-28 February 2002, Abstracts.
95. Rusconi S., La Seta Catamancio S., Citterio P., Kurtagic S., Violin M., Balotta C., et al. Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrobial Agents and Chemotherapy. 44:2000;1328-1332
96. Sankatsing, S., Weverling, G., van't Klooster, G., Prins, J., & Lange, J. TMC125 monotherapy for 1 week results in a similar initial rate of decline of HIV-1 RNA as therapy with a 5-drug regimen. In Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections (no. 5, p. 54). Seattle, Washington, USA, 24-28 February 2002, Abstracts.
97. Sanne I., Piliero P., Squires K., Thiry A., Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naïve subjects. Journal of Acquired Immune Deficiency Syndrome. 32:2003;18-29
98. Schinazi R.F., Mellors J., Bazmi H., Diamond S., Garber S., Gallagher K., et al. DPC 817: A cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants. Antimicrobial Agents and Chemotherapy. 46:2002;1394-1401
99. Schols, D., Claes, S., De Clercq, E., Hendrix, C., Bridger, G., & Calandra, G., et al., AMD-3100 HIV Study Group (2002). AMD-3100, a CXCR4 antagonist, reduced HIV viral load and X4 virus levels in humans. In Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections (no. 2, p. 53). Seattle, Washington, USA, 24-28 February 2002, Abstracts.
100. Schols, D., Claes, S., Hatse, S., Princen, K., Vermeire, K., & De Clercq, et al. (2002). Anti-HIV activity profile of AMD070, an orally bioavailable CXCR4 antagonist H. In Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections (no. 563). Boston, MA, USA, 10-14 February 2003, Abstracts.
101. Schols, D., Claes, S., Hatse, S., Princen, K., Vermeire, K., & De Clercq, E., et al. (2003). Anti-HIV activity profile of AMD070, an orally bioavailable CXCR4 antagonist. In Proceedings of the 16th International Conference on Antiviral Research. Savannah, GA, USA, 27 April-1 May 2003; Antiviral Research, 57, A39.
102. Schwartz, R., Kazanjian, P., Slater, L., Hathaway, B., Markowitz, M., & Wheeler, D., et al. (2002). Resistance to tipranavir is uncommon in a randomized trial of tipranavir/ritonavir (TPV/RTV) in multiple PI-failure patients (BI 1182.2). In Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections (no. 562-T, p. 261). Seattle, Washington, USA, 24-28 February 2002, Abstracts.
103. Shaw-Reid C.A., Munshi V., Graham P., Wolfe A., Witmer M., Danzeisen R., et al. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2, 4-dioxobutanoic acid. Journal of Biological Chemistry. 278:2003;2777-2780
104. Staszewski, S., Gallant, J., Pozniak, A., Suleiman, J. M. A. H., Dejesus, E., & Koenig, E., et al. (2002). Efficacy and safety of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected patients naïve to antiretroviral therapy (ART): 48-week interim results. In Proceedings of the XIV International Acquired Immunodeficiency Syndrome Conference (no. Or17). Barcelona, Spain, 7-12 July 2002, Abstracts.
105. Staszewski, S., Gallant, J. E., Pozniak, A. L., Suleiman, J. M. A. H., DeJesus, E., & Lu, B., et al. (2003). Efficacy and safety of tenofovir DF (TDF) versus stavudine (d4T) when used in combination with lamivudine and efavirenz in antiretroviral naïve patients: 96-week preliminary interim results. In Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections (no. 564b). Boston, MA, USA, 10-14 February 2003, Abstracts.
106. Stevens M., Pannecouque C., De Clercq E., Balzarini J. Inhibition of human immunodeficiency virus by a new class of pyridine oxide derivatives. Antimicrobial Agents and Chemotherapy. 47:2003;2951-2957
107. Stevens M., Pannecouque C., De Clercq E., Balzarini J. Novel human immunodeficiency virus (HIV) inhibitors that have a dual mode of anti-HIV action. Antimicrobial Agents and Chemotherapy. 47:2003;3109-3116
108. Stoddart C.A., Moreno M.E., Linquist-Stepps V.D., Bare C., Bogan M.R., Gobbi A., et al. Antiviral activity of 2′-deoxy-3′-oxa-4′- thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice. Antimicrobial Agents and Chemotherapy. 44:2000;783-786
109. Stoddart, C. A., Bozeman, C. A., & Schinazi, R. F. (2002). Activity of the cytidine analog reverset (RVT) against 3TC-resistant HIV-1 in SCID-hu Thy/Liv mice, HIV DART 2002. Frontiers in drug development for antiretroviral therapies (no. 023). Naples, FL, USA, 15-19 December 2002; Antiviral Research, Abstracts.
110. Strizki J.M., Xu S., Wagner N.E., Wojcik L., Liu J., Hou Y., et al. SCH-C (SCH 351125), an orally bioavailable% small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proceedings of National Academy of United States of America. 98:2001;12718-12723
111. Szczech G.M., Furman P., Painter G.R., Barry D.W., Borroto-Esoda K., Grizzle T.B., et al. Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy. 44:2000;123-130
112. Turner S.R., Strohbach J.W., Tommasi R.A., Aristoff P.A., Johnson P.D., Skulnick H.I., et al. Tipranavir (PNU-140690): A potent, orally bioavaible nonpeptidic HIV protease inhibitor of the 5, 6-dihydro-4-hydroxy-2-pyrone sulfonamide class. Journal of Medical Chemistry. 41:1998;3467-3476
113. Turpin J.A., Buckheit R.W. Jr., Derse D., Hollingshead M., Williamson K., Palamone C., et al. Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription. Antimicrobial Agents and Chemotherapy. 42:1998;487-494
114. Van Bömmel F., Schernick A., Hopf U., Berg T. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. Gastroenterology. 124:2003;586-587
115. Van Der Geest, R., Van Der Sandt, I., Gille, D., Groen, K., Tritsmans, L., & Stoffels, P. (2001). Safety, tolerability and pharmacokinetics of escalating singe oral doses of TMC 114, a novel protease inhibitor (PI) highly active against HIV-1 variants resistant to other Pis. In Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, USA, 16-19 December 2001, Abstracts, I-1934.
116. Van Rompay K.K.A., Schmidt K.A., Lawson J.R., Singh R., Bischofberger N., Marthas M.L. Topical administration of low-dose tenofovir disoproxil fumarate
117. Vermeire K., Zhang Y., Princen K., Hatse S., Samala M.F., Dey K., et al. CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor. Virology. 302:2002;342-353
118. Vermeire K., Bell T.W., Choi H.-J., Jin Q., Samala M.F., Sodoma A., et al. The anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor. Molecular Pharmacology. 63:2003;203-210
119. Vermeire, K., Bell, T. W., Dey, K., Hatse, S., Princen, K., & De Clercq, et al. (2003). The CD4 down-modulating compound, CADA, is synergistic with multiple anti-HIV drugs in vitro, Submitted for publication.
120. Wai J.S., Egbertson M.S., Payne L.S., Fisher T.E., Embrey M.W., Tran L.O., et al. 4-Aryl-2, 4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. Journal of Medical Chemistry. 43:2000;4923-4926
121. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrobial Agents and Chemotherapy. 46:2002;1896-1905
122. Willoughby C.A., Rosauer K.G., Hale J.J., Budhu R.J., Mills S.G., Chapman K.T., et al. 1, 3, 4-Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains. Bioorganic Medical Chemistry and Letters. 13:2003;427-431
123. Yoshimura K., Kato R., Kavlick M.F., Nguyen A., Maroun V., Maeda K., et al. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. Journal of Virology. 76:2002;1349-1358
124. Yoshinaga, T., Sato, A., Fujishita, T., & Fujiwara, T. (2002). S-1360: In vitro activity of a new HIV-1 integrase inhibitor in clinical development. In Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections (no. 8, p. 55). Seattle, Washington, USA, 24-28 February 2002, Abstracts.
125. Zhang X., Pais G.C.G., Svarovskaia E.S., Marchand C., Johnson A.A., Karki R.G., et al. Azido-containing aryl β-diketo acid HIV-1 integrase inhibitors. Bioorganic Medical Chemistry and Letters. 13:2003;1215-1219